JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) Fair Value & Analysis
Consumer Defensive · TH · Market cap 797M THB
Fair value as of: Jun 24, 2026
Analysis
JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) currently trades at 1.72 THB, while our model-based Fair Value estimate is 2.90 THB — implying the stock looks roughly 68.6% undervalued today. We read business quality at 93/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. engages in the research, development, manufacturing, and sales of pharmaceutical, dietary supplementary, traditional medicine, and herbal products in Thailand. It is also involved in manufacturing and selling hemodialysis products and supplies, purified water systems for industrial purposes, and related medical supplies; and services of laboratory research, scientific test and analysis, training and seminar, and consultancy for research fund application businesses. In addition, the company sells products through vending machines. JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. was founded in 1954 and is headquartered in Bangkok, Thailand.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is JSP Pharmaceutical Manufacturing (Thailand) Public Co (JSP) undervalued?
What is the fair value of JSP?
What is the quality score of JSP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.